Sponsors
Introduced January 23, 2025 by H. Morgan Griffith · Last progress January 23, 2025
The bill prioritizes domestic PPE production, quality, and transparency to strengthen supply‑chain resilience and healthcare worker safety, but does so at the likely cost of higher procurement expenses, narrower supplier options, potential shortages in sudden surges, and added administrative and regulatory burdens.
Hospitals, health systems, and first responders will get prioritized domestic PPE and infection‑control supplies during declared public‑health emergencies through guaranteed purchase agreements and domestic‑sourcing targets, reducing reliance on foreign supply and improving surge availability.
Healthcare workers and patients will see improved PPE quality and workplace safety because purchased products must meet CDC/OSHA guidelines and 510(k) clearance and because congressional reporting can drive stronger PPE policies based on documented gaps.
U.S. domestic manufacturers and small businesses will gain more predictable federal and state sales and contracts, supporting manufacturing jobs and onshore supply‑chain resilience.
Taxpayers, hospitals, and governments could face higher costs because guaranteed purchase agreements, surge capacity commitments, and stricter standards increase public spending and procurement prices.
Limiting eligibility to majority U.S.‑owned or headquartered firms and prioritizing domestic supply narrows the supplier pool, which could raise prices, slow procurement, or reduce competition.
In fast‑moving emergencies, a domestic‑only procurement preference may limit access to needed equipment if U.S. production cannot meet sudden demand, risking local shortages for patients and health workers.
Based on analysis of 4 sections of legislative text.
Creates an HHS program to guarantee domestically produced, quality-approved PPE, bars use of federal funds to buy foreign-made PPE (with exceptions), and requires a 1-year report on PPE rules since COVID-19.
Creates an HHS program to contract with eligible U.S.-based manufacturers to guarantee the availability of qualified personal protective equipment (PPE) for public health emergencies, sets phased domestic-sourcing targets for PPE provided to the federal government through 2028, and requires that qualified PPE meet CDC/OSHA quality guidance and FDA 510(k) clearance. Bars use of federal funds by federal, state, or local agencies to procure foreign-made PPE (with existing statutory exceptions) and requires one-year reporting to Congress on changes to federal PPE requirements since the start of the COVID-19 pandemic and their effects on frontline clinicians.